A 19–34-GHz Bridged-T Phase Shifter With High-Pass Phase Compensation Achieving 3.9° RMS Phase Error for 5G NR ...

This study proposes the design, fabrication, and testing of a 3-D integrated transmitter operating at the W band. Detailed analyses of the performance variations before and after packaging of the ...

Anlotinib plus penpulimab has demonstrated encouraging activity and safety in a phase 2 study. In this phase 3 trial, we aimed to assess whether the combination of anlotinib plus penpulimab improved ...

TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.

The low EOT and high κ values were achieved by careful optimization of AFE/FE film thicknesses and HPA conditions near the morphotropic phase boundary (MPB) after field cycling effects. Stable leakage ...

Vor Bio is licensing global rights to a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last ...

“We are excited to advance VK2735 into Phase 3 clinical development, moving one step closer to potentially bringing this important therapeutic to patients with obesity,” said Brian Lian, Ph.D., chief ...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic ...

NEW YORK, June 26, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents ...